Development of a dengue exposure monitor

开发登革热暴露监测器

• 批准号: 10079069
• 负责人: JOHN E MUELLER
• 金额: $ 24.44万
• 依托单位: LYNNTECH, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2021-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10079069
• 关键词: 4 year old; Affinity; Africa; Age; Antibodies; Asia; Biological Assay; Biological Markers; Central America; Child; Clinical Research; Communities; Contracts; Data; Dengue; Dengue Fever; Dengue Infection; Dengue Vaccine; Dengue Virus; Detection; Development; Devices; Diagnostic; Disease; Disease Outbreaks; Exposure to; FDA approved; Flavivirus; Florida; Generations; Human; Immunoglobulin G; Immunoglobulin M; Individual; Infection; Island; Life; Ligands; Medical; Monitor; Peptides; Phage Display; Phase; Plasma; Population; Protocols documentation; Risk; Safety; Sampling; Serological; Serotyping; Signal Transduction; South America; System; Testing; Texas; United States; Vaccination; Vaccines; Virus; Work; combat; electric impedance; high risk; innovation; point of care; portability; programs; user-friendly; vaccine efficacy

PROJECT SUMMARY Approximately 40% of the world’s population, 2.5 billion people, are at risk of contracting dengue fever. The disease is endemic to tropical regions in Central and South America, Africa, and Asia. Outbreaks have also occurred in the southern portions of the United States, including Florida and Texas, as well as the Hawiian islands.The FDA has approved a single vaccine against dengue. Both safety and efficacy of the vaccine depend on whether or not the recipient has been previously exposed to the dengue virus. The potential for severe dengue disease in seronegative individuals receiving the vaccination (especially for children ages 2-4) underscores the need for a field-deployable device to determine if individuals have previously been infected by the dengue virus. There is a concern that a universal vaccination program could have deleterious effects on populations living in regions where infection is the norm. Thus, a rapid, economical, point-of-care (POC) assay to determine if an individual has been exposed to the virus will be significant. Data from this assay will assist the medical community in establishing an anti-dengue vaccination protocol. Lynntech proposes to develop a portable, highly sensitive, and highly specifc diagnostic that is capable of detecting anti-dengue antibodies in human samples. Anti-dengue antibodies will be specifically recognized and captured by high affinity ligands, resulting in the generation of an electrochemical signal reflecting pre- exposure to the dengue virus. The Lynntech system will offer a straightforward, POC means to assess the serological profile of individuals with respect to their previous exposure to the dengue virus. The global need for such an assay bolsters market potential for the Lynntech product.

项目摘要 世界上大约40%的人口，即25亿人，面临感染登革热的风险。的 这种疾病是中美洲和南美洲、非洲和亚洲热带地区的地方病。疫情也 发生在美国南部，包括佛罗里达和得克萨斯州，以及夏威夷州。 美国食品和药物管理局已经批准了一种针对登革热的单一疫苗。疫苗的安全性和有效性 这取决于接受者以前是否接触过登革热病毒。 在接受疫苗接种的血清阴性个体中发生严重登革热疾病的可能性（特别是对于 儿童年龄2-4）强调需要一个现场部署的设备，以确定个人是否有 以前曾感染过登革热病毒。人们担心，普遍的疫苗接种计划可能会 对生活在感染是常态的地区的人口产生有害影响。因此，一种快速、经济、 用于确定个体是否暴露于病毒的护理点（POC）测定将是重要的。数据 将有助于医学界建立抗登革热疫苗接种方案。 Lynntech提出开发一种便携式，高灵敏度和高特异性的诊断方法， 检测人体样本中的登革热抗体。抗登革热抗体将被特异性识别 并被高亲和性配体捕获，导致产生反映预- 接触登革热病毒。Lynntech系统将提供一种简单的POC方法来评估 个体先前接触登革热病毒的血清学特征。的全球需要 因为这样的分析支持了Lynntech产品的市场潜力。